Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.54 USD
+0.10 (4.10%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $2.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Do Options Traders Know Something About Puma (PBYI) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Puma (PBYI) stock based on the movements in the options market lately.
Puma (PBYI) Misses on Q3 Earnings, Cuts Sales View, Stock Down
by Zacks Equity Research
Puma Biotech (PBYI) reports lower-than-expected Q3 earnings and sales. It slashes 2021 Nerlynx sales guidance.
Puma Biotech (PBYI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of -373.91% and -13.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Puma Biotech (PBYI) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.
Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 58.06% and 4.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
by Zacks Equity Research
Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.
Puma Biotech (PBYI) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 37.93% and 31.03%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celcuity (CELC) Soars on Agreement With Pfizer & Study Data
by Zacks Equity Research
Celcuity (CELC) is developing gedatolisib in combination with Pfizer's Ibrance and an endocrine therapy in breast cancer patients. It inks deal to gain exclusive rights to gedatolisib from Pfizer.
Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall
by Zacks Equity Research
Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.
Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's (RHHBY) Phesgo Gets EU Nod to Treat Breast Cancer
by Zacks Equity Research
Roche's (RHHBY) fixed-dose combination of Perjeta and Herceptin administered subcutaneously gets approved by the EC for the treatment of early and metastatic HER2-positive breast cancer.
Why Is Puma Biotech (PBYI) Up 36% Since Last Earnings Report?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma (PBYI) Down 8% on Q3 Earnings Lag, Nerlynx Sales View Cut
by Zacks Equity Research
Puma Biotech (PBYI) falls more than 8% as it misses on both earnings and revenues in the third quarter of 2020. The company trims its 2020 revenue guidance for Nerlynx.
Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of -139.39% and -4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Puma Biotech (PBYI) Down 7.2% Since Last Earnings Report?
by Zacks Equity Research
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Puma's (PBYI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Puma Biotech's (PBYI) bottom and the top line better estimates for the second quarter of 2020.
Puma Biotech (PBYI) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Puma Biotech (PBYI) delivered earnings and revenue surprises of 130.77% and 26.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod
by Zacks Equity Research
Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.
Why the Sell-Off in These 5 Stocks is a Buying Opportunity
by Nilanjan Choudhury
We have zeroed in on five stocks that have witnessed a slump this past week but have a favorable Zacks Rank #1 (Strong Buy) or 2 (Buy).